...
首页> 外文期刊>Statistics in medicine >Titrating and evaluating multi-drug regimens within subjects.
【24h】

Titrating and evaluating multi-drug regimens within subjects.

机译:滴定和评估受试者内的多种药物方案。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The dosing of combination therapies is commonly undertaken empirically by practising physicians, and a coherent algorithm to approach the problem of combination dosing is currently lacking. Current methods of evaluating multiple drug combinations in clinical trials fail to provide information regarding the location of more effective doses when the combination is not found to differ from the standard, even though the absence of a difference does not necessarily mean the new combination is ineffective. Moreover, in studies where the new combination is found more effective, often a large proportion of the study participants obtain no benefit from the trial. Even with early stopping rules, the time these subjects spend on inferior treatments can have lasting detrimental effects, leading to problems with patient enrolment and adherence to study protocol. This paper describes an evolutionary operation (EVOP) direct-search procedure to titrate combination doses within individual patients. The Nelder-Mead simplex direct-search algorithm is used to titrate combinations of drugs within individual subjects. Desirability functions are utilized to define the main response of interest and additional responses or constraints. Statistical methodology for determining whether the titrated treatment combination has resulted in an improvement in subject response and for evaluating for therapeutic synergism is developed. Inferences can then be made about the efficacy of the combination or about the individual drugs that comprise the combination. The advantages of this approach include affording every patient the potential to benefit from the combination under study and permitting the consideration of multiple endpoints simultaneously.
机译:联合疗法的剂量通常由执业医师凭经验进行,并且目前缺乏用于解决联合剂量问题的连贯算法。当没有发现组合与标准品存在差异时,当前在临床试验中评估多种药物组合的方法无法提供有关更有效剂量位置的信息,即使没有差异也不一定意味着新组合无效。此外,在发现新组合更有效的研究中,通常有很大一部分研究参与者没有从试验中受益。即使有早期停止的规则,这些受试者花费在劣等治疗上的时间也会产生持久的有害影响,从而导致患者入院和遵守研究方案的问题。本文介绍了一种进化操作(EVOP)直接搜索程序,可用于确定单个患者内的联合剂量。 Nelder-Mead单纯形直接搜索算法用于滴定各个受试者内的药物组合。期望功能用于定义感兴趣的主要响应以及其他响应或约束。开发了用于确定滴定的治疗组合是否已导致受试者反应改善和评估治疗协同作用的统计方法。然后可以推断出该组合的功效或构成该组合的单个药物的功效。这种方法的优点包括为每个患者提供从研究中的组合中获益的潜力,并允许同时考虑多个终点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号